A side-by-side view of two independent report sets. Different denominators mean percentages describe each dataset only; they do not establish a head-to-head result.
The Tirzepatide panel is calculated only from published Tirzepatide reports. The Retatrutide panel is calculated only from published Retatrutide reports. Source communities, stated goals, time windows, concurrent compounds, and the completeness of each report may differ. Those differences can move a percentage even when the underlying experiences are not directly comparable.
Use this page to see the shape of each indexed public record: how many reports are available, which effects recur, what side effects are stated, and whether onset or dose data is sufficiently structured. Then open the individual feeds to inspect provenance. The display is descriptive and does not rank either compound.
The numbers
0 published reports are currently available. We wait for a minimum sample before showing percentages.
No structured Tirzepatide reports are published yet. New reports are reviewed before they enter the aggregate.
The numbers
0 published reports are currently available. We wait for a minimum sample before showing percentages.
No structured Retatrutide reports are published yet. New reports are reviewed before they enter the aggregate.
Aggregated from source-linked public reports. Every indexed report links to its source. This is anecdotal evidence — not clinical data. How we aggregate →